tiprankstipranks
Shanghai Fosun Pharmaceutical (Group) Co Class H (HK:2196)
:2196

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

Compare
2 Followers

2196 Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

3.62%94.40%
Insiders
― Other Institutional Investors
94.40% Public Companies and
Individual Investors

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Class H lowest stock price was HK$11.32 and its highest was HK$19.50 in the past 12 months.
    What is Shanghai Fosun Pharmaceutical (Group) Co Class H’s market cap?
    Shanghai Fosun Pharmaceutical (Group) Co Class H’s market cap is HK$66.62B.
      When is Shanghai Fosun Pharmaceutical (Group) Co Class H’s upcoming earnings report date?
      Shanghai Fosun Pharmaceutical (Group) Co Class H’s upcoming earnings report date is Mar 31, 2025 which is in 37 days.
        How were Shanghai Fosun Pharmaceutical (Group) Co Class H’s earnings last quarter?
        Shanghai Fosun Pharmaceutical (Group) Co Class H released its earnings results on Oct 30, 2024. The company reported HK$0.31 earnings per share for the quarter, missing the consensus estimate of HK$0.315 by -HK$0.005.
          Is Shanghai Fosun Pharmaceutical (Group) Co Class H overvalued?
          According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Shanghai Fosun Pharmaceutical (Group) Co Class H pay dividends?
            Shanghai Fosun Pharmaceutical (Group) Co Class H pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 2.05%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Class H dividends here
              What is Shanghai Fosun Pharmaceutical (Group) Co Class H’s EPS estimate?
              Shanghai Fosun Pharmaceutical (Group) Co Class H’s EPS estimate is 0.29.
                How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Class H have?
                Shanghai Fosun Pharmaceutical (Group) Co Class H has 551,940,500 shares outstanding.
                  What happened to Shanghai Fosun Pharmaceutical (Group) Co Class H’s price movement after its last earnings report?
                  Shanghai Fosun Pharmaceutical (Group) Co Class H reported an EPS of HK$0.31 in its last earnings report, missing expectations of HK$0.315. Following the earnings report the stock price went up 2.606%.
                    Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Class H?
                    Currently, no hedge funds are holding shares in HK:2196
                    ---

                    Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

                    Company Description

                    Shanghai Fosun Pharmaceutical (Group) Co Class H

                    Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.
                    ---

                    2196 Stock 12 Month Forecast

                    Average Price Target

                    HK$14.22
                    ▼(-8.85% Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","16":"HK$16","19":"HK$19","22":"HK$22","25":"HK$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.2187827878,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$14.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.2187827878,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$14.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.2187827878,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$14.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,16,19,22,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.127598675984615,14.13519735196923,14.142796027953846,14.150394703938462,14.157993379923077,14.165592055907693,14.173190731892307,14.180789407876922,14.188388083861538,14.195986759846154,14.20358543583077,14.211184111815385,{"y":14.2187827878,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.127598675984615,14.13519735196923,14.142796027953846,14.150394703938462,14.157993379923077,14.165592055907693,14.173190731892307,14.180789407876922,14.188388083861538,14.195986759846154,14.20358543583077,14.211184111815385,{"y":14.2187827878,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.12,14.127598675984615,14.13519735196923,14.142796027953846,14.150394703938462,14.157993379923077,14.165592055907693,14.173190731892307,14.180789407876922,14.188388083861538,14.195986759846154,14.20358543583077,14.211184111815385,{"y":14.2187827878,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.365,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.89,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.225,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.409,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.31,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.836,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.542,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.972,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.128,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.037,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.979,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.979,"date":1696118400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.12,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Sino Biopharmaceutical
                    CSPC Pharmaceutical Group
                    Livzon Pharmaceutical Group
                    China Resources Pharmaceutical Group Ltd.
                    Kingworld Medicines Group Ltd.

                    Best Analysts Covering 2196

                    1 Year
                    No data currently available
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis